alexa The Current Molecular Site of the Myeloproliferative Neoplasms - TET-à- tête with the JAKpot but no LNK so far to Resolve Complexity | OMICS International | Abstract
ISSN: 2329-6917

Journal of Leukemia
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

The Current Molecular Site of the Myeloproliferative Neoplasms - TET-à- tête with the JAKpot but no LNK so far to Resolve Complexity

Oliver Bock*

Institute of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Germany

*Corresponding Author:
Oliver Bock
Department of Psychiatry
Social Psychiatry and Psychotherapy
Hannover Medical School
Carl-Neuberg-Strasse 1
30625 Hannover, Germany
Tel: 0049-511-532-6748
Fax: 0049-511-532-6648
E-mail: [email protected]

Received date February 20, 2013; Accepted date April 05, 2013; Published date April 08, 2013

Citation: Bock O (2013) The Current Molecular Site of the Myeloproliferative Neoplasms - TET-á-tête with the Jackpot but no LNK so far to Resolve Complexity. J Leuk (Los Angel) 1:108. doi: 10.4172/2329-6917.1000108

Copyright: © 2013 Bock O. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

The myeloproliferative neoplasms essential thrombocythemia (ET), polycythemia vera (PV) and primary myelofibrosis (PMF) are clonal haematological stem cell disorders with different clinical courses and prognosis. The predominant feature in these entities is the overproduction of at least one cellular lineage in the bone marrow. Peripheral blood cells are terminally differentiated and functional but may affect e.g. blood viscosity with a high hematocrit in PV leading to the risk for thrombotic events or bleeding. PMF, preceded by a hypercellular pre-fibrotic stage, has the highest risk to develop manifest bone marrow fibrosis with consecutive bone marrow failure. The risk for a blast crisis and transformation into secondary acute leukemia is also particularly high in PMF and PV but rather uncommon in ET. Even though distinguishable from each other by clinical and histopathological criteria ET, PV and PMF may show overlaps, i.e. in early stages. Moreover, reactive hypercellular states in the bone marrow may mimic a myeloproliferative neoplasm (MPN) making definite molecular markers very useful. ET, PV and PMF currently share a number of molecular defects which are detectable by accurate technologies and, in a diagnostic sense, subsequently allow a clear-cut discriminationfrom reactive states. Some of these molecular defects are frequent in the stage of secondary acute leukemia; others were proposed to be potential predictors for a progression of the disease course. At best, the protagonist of molecular defects in Ph- MPN, the Janus Kinase 2 with its V617F mutation, became a therapeutic target by using small molecule inhibitors. This review focuses on the hitherto discovered molecular defects in ET, PV and PMF in chronic phase and disease progression, highlights some of the current and upcoming therapies and proposes a disease model.

Keywords

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version